This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Merck Won't Yield on Yield

Merck still gets high marks from credit-rating firms. At Moody's Investors Service, for example, Merck ranks No. 4 among 21 drug companies. Moody's looks at many factors to develop its credit ratings, and Merck's free-cash-to-debt ratio is still in the high-grade range, says the agency's Michael Levesque. The operating-cash-to-debt ratio, which excludes dividends, still qualifies for a top rating, he says.

Levesque says Merck's "Aa3" rating should hold this year and next as long as the company can generate $1.5 billion in free cash flow annually and keep the Vioxx liabilities under $10 billion. The key to the near-term rating is the Vioxx litigation, Levesque says.

Dividend Dilemmas

Another type of lawsuit is weighing on the dividend strategy at Bristol-Myers Squibb (BMY), which has the highest yield among its peers and a weaker credit rating than Merck. Like Merck, it suffers from too many big-revenue drugs losing, or about to lose, patent protection, and few promising replacements on the horizon.

Bristol-Myers is awaiting a trial challenging its U.S. patent for its biggest drug, the anticoagulant Plavix. A court date has been set for April 2006. The company and its partner Sanofi-Aventis (SNY) are fighting two generic drugmakers that are trying to invalidate a patent that runs into 2011.

"An adverse outcome would cause us to re-evaluate operational and financial needs, including the dividend," says Jeffrey Schoenborn, a Bristol-Myers spokesman, whose company is developing contingency plans for a Plavix ruling. Plavix produced $980 million in third-quarter sales, or 20% of corporate revenue.

The quarterly payout is 28 cents a share, a level it has held for four years. Meanwhile, Bristol-Myers remains in the Wall Street doghouse, as only one out of 25 analysts who cover it has a buy rating, according to Thomson First Call.

Litigation made Wyeth (WYE) face a dividend decision in the late 1990s and early 2000s because of legal liabilities related to the diet drugs Pondimin and Redux, which were withdrawn from the market in 1997.

3 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,136.72 +4.75 0.03%
S&P 500 1,999.75 +0.77 0.04%
NASDAQ 4,559.8590 +7.10 0.16%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs